Sedalgin Plus

Quick links to important sections

Sedalgin Plus

Selected form

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sedalgin Plus

Property Description
Active Ingredients Sodium Metamizole, Caffeine, Thiamine Hydrochloride
Form Oral Solid (Tablet)
Pharmacological Class Compound Analgesic and Antipyretic Agent
Common Use Relief of pain and fever
Origin Fixed-dose combination of synthetic compounds and an essential vitamin

Sedalgin Plus: Definition and Pharmacological Classification

Sedalgin Plus is a fixed-dose combination product administered via the oral route, which is classified as a compound analgesic and antipyretic agent with distinct spasmolytic properties. This medicinal entity is a synthesis of three active pharmaceutical compounds working together to manage discomfort. The drug's primary component, Sodium Metamizole (Dipyrone), is recognized as a pyrazolone derivative within the World Health Organization's ATC classification system. This classification establishes the drug’s core function of providing potent relief from pain and elevated body temperature.

What are the Active Ingredients and Form?

The core composition of Sedalgin Plus features the three active ingredients: Sodium Metamizole, Caffeine, and Thiamine Hydrochloride (Vitamin B1). This medication is supplied in an oral solid form, typically a tablet. The formulation combines two synthetic compounds with an essential B-complex vitamin. Sodium Metamizole is considered a potent nonacid nonopioid analgesic that possesses spasmolytic properties. Caffeine is a widely recognized central nervous system (CNS) stimulant belonging to the methylxanthine class. Thiamine Hydrochloride is included due to its established biological role in supporting nervous system function and energy metabolism.

High-Level Purpose: Combining Pain Relief and CNS Support

The general purpose of this medication is to achieve a compounded therapeutic benefit by utilizing multiple pharmacological actions at once. Sodium Metamizole provides strong pain relief, while the CNS stimulant properties of Caffeine function to heighten alertness and may enhance the analgesic effect. This strategic formulation is often employed in situations where discomfort, such as a severe headache or muscle ache, is accompanied by fatigue or muscle tension. The fixed combination aims to provide comprehensive symptomatic relief while counteracting potential drowsiness, thereby supporting the patient's functional capacity.

Regulatory References

  1. NIH StatPearls on Caffeine
  2. MedlinePlus Drug Information on Thiamine (Vitamin B1)

What side effects are possible with Sedalgin Plus?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and regulatory safety characteristics associated with the active components of Sedalgin Plus, based strictly on government regulatory documents.

Serious Adverse Reactions and Frequency

The most critical documented risks, primarily linked to Sodium Metamizole, are classified as rare or of unknown frequency but require critical regulatory attention:

  • Agranulocytosis: A severe, potentially fatal reduction in white blood cells. This reaction is classified as rare in official regulatory documents.
  • Acute Liver Injury (DILI): Drug-Induced Liver Injury, including severe hepatitis or liver failure, is a serious adverse reaction, often listed as very rare or of unknown frequency.
  • Severe Skin Reactions: Serious conditions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are documented serious risks.
  • Anaphylactic Shock: Severe, immediate-onset allergic reactions.

Common and System-Based Effects

Side effects are often categorized by the system affected. Common, non-serious effects include:

  • Blood and Immune System Disorders: Beyond Agranulocytosis, hypersensitivity reactions may occur.
  • Nervous System Disorders: Effects like Insomnia, Nervousness, and Anxiety are associated with the Caffeine component.
  • Gastrointestinal Disorders: Nausea, vomiting, or abdominal discomfort.
  • Cardiovascular Effects: Palpitations or an increase in blood pressure due to the Caffeine component.

Regulatory Safety Constraints

Official labeling defines specific constraints and instructions for healthcare providers:

  • Immediate Discontinuation: Treatment must be stopped immediately if symptoms suggestive of Agranulocytosis (e.g., fever, sore throat) or Acute Liver Injury (e.g., jaundice) appear.
  • Contraindications: Use is prohibited in individuals with a history of Agranulocytosis caused by Metamizole or related drugs.
  • Population Notes: Regulatory documents advise against using the product in the last three months of pregnancy and during lactation.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage is officially documented as a severe intoxication, requiring immediate medical attention due to the high potential for fatal outcomes from the active components. The recognized clinical profile is characterized by pronounced central nervous system (CNS) effects, including confusion, agitation, muscle tremors, and escalating to convulsions (seizures). Cardiovascular instability is a documented manifestation, presenting as tachycardia (rapid heart rate), irregular heart rhythms, and severe hypotension.

The most severe consequences listed in regulatory sources include ventricular fibrillation, cardiac arrest, and coma. Acute organ damage, such as rhabdomyolysis and acute kidney failure, may result from metabolic disturbances like severe metabolic acidosis. A separate life-threatening risk associated with the metamizole component is the documented potential for drug-induced agranulocytosis. Lower exposures are noted as potentially life-threatening in children.

Regulatory authorities mandate that patients seek immediate medical attention and contact emergency services for any suspected overdosage. Management is strictly defined as symptomatic and supportive; no specific antidote is known. Hospital monitoring, including continuous cardiac monitoring (ECG) and laboratory testing for electrolyte abnormalities, is typically required to address the documented acute risks and complications.

Therapeutic Uses of Sedalgin Plus

What Sedalgin Plus Treats: Main Uses and Benefits

The combination of active ingredients is commonly applied across therapeutic domains to provide symptomatic support for patients experiencing heightened discomfort. Its main component is used as an analgesic, antipyretic, and spasmolytic agent across many countries for severe pain and fever.

The medication is primarily used to help manage moderate to severe pain stemming from various sources. This generally includes recurrent headache patterns, such as tension-type headache and certain migraine manifestations, as well as pain related to the musculoskeletal system and peripheral nerves (e.g., radiculitis, neuralgia). The drug is also applied in conditions marked by heightened symptoms of smooth muscle contraction, specifically during episodes of visceral pain, such as renal colic, intestinal spasms, and the discomfort associated with painful menstruation (dysmenorrhea).

“The compound is generally used when short-term symptomatic assistance is needed to address pain, fever, and associated tension in a single therapeutic approach.”

By addressing these symptom clusters, the medication provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort during symptomatic periods. Furthermore, its effect of supporting the reduction of elevated body temperature (fever) alongside its ability to help mitigate associated fatigue assists with maintaining functional stability.


Quick Fact: Relief for Combined Pain and Spasm The formulation is commonly applied in clinical settings that involve acute or unstable symptom patterns where pain is accompanied by fever or a cramping, spastic component.

Eligibility and Restrictions for Use

The official eligibility for Sedalgin Plus is dictated by the contraindications and restrictions of its primary component, Metamizole, as documented by regulatory bodies.

Contraindicated Populations (Absolute Non-Eligibility)

Use is prohibited for individuals with a history of hypersensitivity to Metamizole or other pyrazolones. It is also contraindicated in patients with impaired bone marrow function or established diseases of the hematopoietic system.

Classification Population Group Regulatory Status
Age Restriction Infants below 3 months or below 5 kg Contraindicated
Hereditary Acute hepatic porphyria or G6PD deficiency Contraindicated

Restricted Use and Special Considerations

The standard tablet formulation is typically approved for adults and adolescents 15 years of age or older (and >53 kg). Use is not recommended for children younger than 15, as the fixed dose is inappropriate for weight-based dosing.

Stage Regulatory Status
Pregnancy (3rd Trimester) Contraindicated
Pregnancy (1st & 2nd Trimester) Advised against/Restricted
Lactation/Breastfeeding Not recommended/Avoided

Use requires caution in the elderly and in patients with impaired renal or hepatic function, where prolonged elimination may occur, and multiple high doses are advised against.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sedalgin Plus, which contains Sodium Metamizole and Caffeine, has documented interaction patterns primarily through the Metamizole component's effect on drug metabolism.


Pharmacokinetic and Exposure-Altering Interactions

The active metabolite of Metamizole is documented as a moderate to strong inducer of several CYP enzymes, including CYP3A4, CYP2B6, and CYP2C19. This induction may reduce the plasma concentration and clinical efficacy of co-administered drugs that are substrates of these enzymes, such as the immunosuppressants Cyclosporine and Tacrolimus, and certain antidepressants or antiretroviral agents (e.g., Bupropion, Efavirenz).

Conversely, co-administration with Methotrexate may lead to increased plasma concentrations and heightened toxicity of Methotrexate, with this risk being elevated in patients with existing renal impairment. Metamizole is also noted to decrease the effectiveness of various antihypertensive agents (e.g., ACE inhibitors, sartans).


Pharmacodynamic and Other Constraints

A clinically relevant interaction is the potential for Metamizole to inhibit the antiplatelet effect of Acetylsalicylic acid (ASA) when taken simultaneously. This requires consideration regarding the timing of administration to maintain ASA's cardioprotective benefit.

Due to the Caffeine content, excessive intake of other caffeine-containing products should be managed to avoid CNS overstimulation effects. Co-administration with alcohol is also noted for the risk of additive central nervous system effects or potentiated hypotension.

Mechanism of Action

Central Attenuation of Pain and Thermoregulation Signals

This domain covers the primary action of Sodium Metamizole, which acts within the Central Nervous System (CNS) to attenuate nociceptive signal transmission. It does this by inhibiting the COX-3 enzyme in the hypothalamus, thereby altering the hypothalamic temperature set-point, and by modulating the descending pain pathway via CB₁ and µ-Opioid receptors, leading to attenuation of nociceptive signaling.


Smooth Muscle Relaxation and Synergistic Potentiation

The drug exerts a direct spasmolytic effect by modulating Ca^2+ dynamics in smooth muscle cells, which results in the relaxation of smooth muscle. Furthermore, Caffeine provides a synergistic benefit by antagonizing inhibitory Adenosine Receptors in the CNS, functionally enhancing Metamizole's central action while modulating the CNS arousal system.


Metabolic Support for Neuronal Integrity

This mechanism is driven by Thiamine (Vitamin B₁), which is converted into a key coenzyme, Thiamine Diphosphate ( ThDP), essential for carbohydrate metabolism within nerve cells. This action supports the structural and functional integrity of neuronal pathways, contributing to the functional characteristics of the regulatory systems targeted by the other active components.

Dosage and Administration Information

Official Administration Guidelines for Sedalgin Plus

This section outlines the usage instructions for Sedalgin Plus tablets, based on information found in documentation and prescribing information.

Administration Scope

Instruction Domain Official Requirement
Route of Administration Oral. The tablet must be swallowed whole.
Dosing Schedule Adults: The standard single dose is 1 to 2 tablets. Dosing must not exceed the prescribed maximum single dose. The total daily intake must not exceed the maximum dose specified on the official label.
Frequency and Timing Doses may be repeated as necessary, generally every 4 to 8 hours. A minimum time interval between doses (e.g., 4 hours) must be maintained.
Administration Conditions The tablets may be taken with or without food. Use must be limited to the shortest possible duration.
Special Restrictions Do not exceed the stated maximum daily intake. Individuals should limit the concurrent consumption of caffeine from other sources (e.g., coffee, tea) while taking this medication.
Age-Group Rules Use in pediatric populations is generally restricted or requires a specific weight-based dose calculation. Dose adjustments or extended dosing intervals are often necessary for patients with impaired kidney or liver function.

Procedural Structure

  1. Confirm the minimum required time interval has elapsed since the previous dose.
  2. Take the approved dose (1 or 2 tablets) by mouth.
  3. Swallow the tablet whole with a sufficient amount of water.
  4. Ensure the total number of tablets taken does not exceed the maximum limit within a 24-hour period.

These official administration guidelines define the standardized use of Sedalgin Plus, establishing the correct oral route and the fixed dosing limits necessary for its appropriate intake. Adherence to the minimum time between doses and the maximum daily dose is critical to comply with regulatory standards.

Recent Clinical Evidence

Sedalgin Plus: Recent Clinical Evidence

Overview of Clinical Research

Research into Sedalgin Plus has explored its effect on patient-reported outcomes in individuals with moderate-to-severe pain. Research protocols included investigation of the drug's properties, which involved examining its interaction with Substance P receptors.

Studies that examined the use of the drug in combination with opioids were not identified in certain reviews. Research regarding the use of the drug in individuals with a history of heart disease was also conducted in some trials.


Key Study Findings: Pain Reduction

Studies evaluated whether changes in pain scores were observed over a 12-week period. Research also examined the effects of the drug when studied in combination with standard Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Studies investigated whether the frequency of pain episodes was lower in participants receiving Sedalgin Plus. Findings from different trials varied regarding the observed effects on pain outcomes. One study examined the time to onset of an observable change in pain scores among participants, and initial changes were reported in some individuals. Research findings also evaluated the effects of the drug compared to placebo in chronic neuropathic pain settings.


Safety and Tolerability

Studies specifically examined the effects of the drug in older adults. The information provided is descriptive of research findings and is intended only to summarize the scope of the clinical research conducted.

Frequently Asked Questions (FAQ)

Common questions about Sedalgin Plus (FAQ)


Q: Does Sedalgin Plus contain ingredients that can cause drowsiness?

Official documents indicate that while the product contains a stimulant (caffeine), certain components may cause central nervous system effects. Potential side effects listed include drowsiness or fatigue, and concentration problems. These effects are reported alongside stimulating effects such as anxiety and insomnia.


Q: How long after taking Sedalgin Plus should I expect to feel an effect?

According to the official product information for Metamizole, the primary active ingredient, a noticeable analgesic effect can be expected relatively quickly. A clear change in pain scores is often reported approximately 30 to 60 minutes after taking the oral dose.


Q: Is it common to feel a little dizzy after using Sedalgin Plus?

Regulatory sources list both dizziness (vertigo) and low blood pressure (hypotension) among the potential side effects associated with the Metamizole component. Experiencing severe or persistent symptoms is a reason to discuss the issue with a healthcare professional.


Q: Are there specific food groups or beverages I should avoid while taking this medicine?

Regulatory guidance advises limiting or avoiding the consumption of two specific types of products while using this medicine. These include alcohol, due to the risk of additive central nervous system effects, and other caffeine-containing products to avoid overstimulation.


Q: Can Sedalgin Plus be used for chronic, long-term conditions?

Official administration guidelines consistently state that this medication should be limited to the shortest possible duration. Some regulatory assessments have noted that more long-term studies are required to fully determine the safety profile of the Metamizole component with intermediate- or long-term use.


Q: Is Sedalgin Plus considered safe for elderly people?

Regulatory documents advise caution when the drug is administered to elderly individuals. This is often due to the potential for the drug to be eliminated from the body more slowly, which may require adjustments to the dosing interval.


Q: What happens if Sedalgin Plus is taken for too many days in a row?

Official guidelines emphasize limiting the use to the shortest possible duration. Using the medication for prolonged periods or excessively may increase the risk of serious, though rare, adverse reactions. These documented risks include agranulocytosis and acute liver injury.


Q: Can I take Sedalgin Plus if I have a history of stomach problems?

Compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs), the drug is generally noted to have a favorable safety profile concerning the stomach and intestines. However, common side effects do include general gastrointestinal discomfort, such as nausea and vomiting.


Q: Are headaches a potential side effect of Sedalgin Plus?

Headaches are explicitly listed in regulatory documents as a potential side effect associated with the use of the drug's active ingredients. This may be related to the central nervous system effects of the combination components.


Q: Can Sedalgin Plus affect my ability to drive or operate machinery?

Official product information advises that the ability to drive and operate complex machinery may be impaired while taking this medicine, particularly when combined with alcohol. Regulatory warnings indicate that caution is necessary until a person is familiar with the drug’s effects.


Q: What does 'contraindication' mean in the context of Sedalgin Plus use?

A contraindication is a technical medical term used in official documentation to describe a factor or condition that absolutely prohibits the use of a medicine because the potential for harm outweighs any benefit. For Sedalgin Plus, regulatory documents list specific conditions such as acute hepatic porphyria or the third trimester of pregnancy as contraindications.


Q: Is Sedalgin Plus safe to take if I have high blood pressure?

Regulatory information indicates that the drug may cause palpitations and a transient increase in blood pressure. The drug may also reduce the effectiveness of certain blood pressure-lowering agents (antihypertensives). Caution is advised for patients with existing cardiovascular issues.


Q: Does Sedalgin Plus interact with blood thinners like warfarin?

The Metamizole component can induce certain metabolic enzymes (CYP enzymes). This effect may reduce the concentration of certain co-administered drugs in the bloodstream, including some oral anticoagulants (blood thinners) like warfarin. Such interactions are typically managed by a healthcare professional.


Q: Why is the drug not recommended for people with certain heart conditions?

Regulatory documents cite specific reasons why the drug is contraindicated or restricted for people with certain cardiovascular diseases. These restrictions relate to conditions such as low blood pressure (hypotension) or the risk of premature closing of a fetal heart structure (ductus arteriosus) if used in late pregnancy.


Q: Is it normal to feel a mild burning sensation in the stomach after taking Sedalgin Plus?

The official side effect profile lists general abdominal discomfort and nausea as common issues affecting the stomach and intestines. Severe or persistent symptoms are typically discussed with a healthcare professional.


Q: Can Sedalgin Plus interact with medications for depression or anxiety?

The active ingredient Metamizole can induce certain enzymes responsible for breaking down other medications (CYP enzymes). This is documented to potentially reduce the plasma concentration and efficacy of co-administered drugs, including certain types of antidepressants (such as Bupropion).


Q: How long does the effect of Sedalgin Plus typically last?

Official information indicates that the active metabolite of Metamizole has a biological half-life ranging from approximately 2.6 to 3.5 hours. For this reason, repeat doses are typically structured at intervals of 4 to 8 hours as necessary, as outlined in administration guidelines.


Q: Is Sedalgin Plus available without a prescription in some places?

The regulatory status of the key active ingredient, Metamizole, varies widely across the globe. It is sold by prescription or over-the-counter (OTC) in many regions in Europe, South America, and Asia. However, it is prohibited from sale in other countries, including the United States, the United Kingdom, and Australia.


Q: Does Sedalgin Plus have any potential for misuse or dependency?

Sedalgin Plus is classified as a non-opioid analgesic and is not subject to special controlled substance scheduling based on its formula. However, one regulatory-reviewed study noted that the development of tolerance to the pain-relieving effects of Metamizole may occur with repeated administration.


Q: Is Sedalgin Plus known to interact with birth control pills?

Official product information states that the use of this drug can reduce the effectiveness of hormonal contraceptives, such as birth control pills. Due to this risk, the need for additional contraceptive methods is a common topic for discussion with a prescribing healthcare provider.


Q: Does Sedalgin Plus treat inflammation or just mask the pain?

Metamizole is primarily classified in official documents as an analgesic (pain-reliever) and an antipyretic (fever-reducer) agent with spasmolytic (muscle-relaxing) properties. It is documented to possess only weak anti-inflammatory activity and does not share the full mechanism of action of conventional NSAIDs.


Q: Are there any common interactions with herbal supplements and Sedalgin Plus?

General regulatory guidance consistently advises individuals to inform their healthcare providers about all other products they are taking, including vitamins, over-the-counter medicines, and any herbal supplements or tonics. No specific common herbal interactions are documented in the provided authoritative sources.


Q: Is it possible to develop a tolerance to Sedalgin Plus over time?

Some studies, including those reviewed in regulatory contexts, have specifically observed the development of tolerance to the antinociceptive (pain-blocking) effects of the Metamizole component. This effect may occur when the drug is used repeatedly over a certain period of time.

How should Sedalgin Plus be stored and disposed of?

How to Store and Dispose of Sedalgin Plus?

The official storage and disposal instructions for Sedalgin Plus are set by regulatory agencies to maintain drug integrity and ensure safety.


Storage Requirements

Sedalgin Plus must be stored at room temperature and below 25 C or 30 C, depending on the specific product label. It is mandatory to store in the original container and protect from light and moisture. To prevent accidental ingestion, the medication must always be kept out of the sight and reach of children (official regulatory language).


Disposal

Unused or expired Sedalgin Plus must be disposed of according to local pharmaceutical waste regulations. Do not dispose of the medication via wastewater (flushing down the toilet) or general household trash. Instead, utilize a local drug take-back program or follow the government-specified disposal steps for non-hazardous medicines when a take-back program is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sedalgin Plus found in:

A-Z Index: